摘要
控制免疫系统主动攻击肿瘤组织的能力将会是一种与癌症持续攻击博斗的非凡武器。不幸的是,癌症治疗还没有可以获得这种控制力的安全有效方法。为了克服这种控制的障碍,白介素12 (IL-12)肿瘤靶向质粒DNA可以被安全投递到常见肿瘤,并且这些治疗可以诱导处理后和未经处理的肿瘤的抗癌免疫应答。在此,电穿孔介导的ttIL-12pDNA在犬自然发生肿瘤的剂量递增研究中表现出安全且耐受性良好。在剂量递增研究中存活的犬给予3800 μg pDNA,分配于 5种独立的犬磷状细胞癌,相当于I期临床试验服用的野生型IL-12 pDNA剂量。任何一个病人在5种不同剂量水平下未发生严重不良事件,并且参数测试只记录了轻微短暂的变化。在治疗与未治疗的病灶中的临床反应分析和mRNA免疫标志物检测暗示:ttIL-12 pDNA 治疗在少数肿瘤中可以引起病灶治疗及远处转移病灶的抗肿瘤免疫应答。这些观察结果表明ttIL-12 pDNA临床剂量可以被安全服用,并且 这些治疗会影响处理过和未处理的转移灶。
关键词: 癌症,犬,电穿孔,基因治疗,免洗疗法,白细胞介素12,肿瘤靶向
Current Gene Therapy
Title:Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions
Volume: 15 Issue: 1
Author(s): Jeffry Cutrera, Glenn King, Pamela Jones, Kristin Kicenuik, Elias Gumpel, Xueqing Xia and Shulin Li
Affiliation:
关键词: 癌症,犬,电穿孔,基因治疗,免洗疗法,白细胞介素12,肿瘤靶向
摘要: The ability to control the immune system to actively attack tumor tissues will be a marvelous weapon to combat the persistent attack of cancer. Unfortunately, safe and effective methods to gain this control are not yet available as cancer therapies. To overcome the impediments to this control, tumor-targeted (tt) Interleukin 12 (IL-12) plasmid DNA can be safely delivered to accessible tumors, and these treatments can induce antitumor immune responses in both the treated and untreated tumors. Here, electroporationmediated ttIL-12 pDNA treatments are shown to be safe and well tolerated in a dose escalation study in canines bearing naturally-occurring neoplasms. The final patient in the dose-escalation study received up to 3,800 μg pDNA distributed among five separate squamous cell carcinoma tumors in doses equivalent to those administered in a Phase I trial with wildtype IL-12 pDNA. Not a single severe adverse event occurred in any patient at any of the five dose levels, and only minor, transient changes were noted in any tested parameter. Clinical response analysis and immune marker mRNA detection of treated and non-treated lesions suggest that ttIL-12 pDNA treatments in only a few tumors can elicit antitumor immune responses in the treated lesions as well as distant metastatic lesions. These observations and results demonstrate that ttIL-12 pDNA can be safely administered at clinical levels, and these treatments can affect both treated and nontreated, metastatic lesions.
Export Options
About this article
Cite this article as:
Jeffry Cutrera, Glenn King, Pamela Jones, Kristin Kicenuik, Elias Gumpel, Xueqing Xia and Shulin Li , Safety and Efficacy of Tumor-Targeted Interleukin 12 Gene Therapy in Treated and Non-Treated, Metastatic Lesions, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127093654
DOI https://dx.doi.org/10.2174/1566523214666141127093654 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry Efficacy and Safety of Combined Radiotherapy with EGFR Inhibitors and Chemotherapy for Laryngeal Organ Preservation in Patients with Locally Advanced Hypopharyngeal Carcinomas
Current Cancer Drug Targets Branched Peptides for the Modulation of Protein-Protein Interactions: More Arms are Better than One?
Current Medicinal Chemistry The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Steroids and the Immune Response in Graves Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Exploration of Chemopreventive Potential of Linalool in Targeting Lung Cancer Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Disruption of Cell Death Signaling in Cancer: Impact on Disease Prognosis and Response to Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Current Pharmaceutical Design